Cialis (Tadalafil) and Hormonal Contraceptives: Drug Interaction Review

Why This Combination Raises Questions

Tadalafil (Cialis) is FDA-approved for erectile dysfunction and benign prostatic hyperplasia in men, but physicians increasingly prescribe it off-label for women with Raynaud phenomenon, pulmonary arterial hypertension, and female sexual arousal disorder [1]. That expanding use puts tadalafil on the medication list alongside hormonal contraceptives for a growing number of patients. Both drug classes share CYP3A4 as a primary metabolic pathway, which is the enzyme system most likely to produce a pharmacokinetic interaction [2].

The clinical question is straightforward: does tadalafil change contraceptive hormone levels (risking unintended pregnancy), and do contraceptive hormones change tadalafil levels (risking side effects or reduced efficacy)? The short answer is no on both counts. The FDA label for tadalafil reports a dedicated crossover study in healthy women that found no meaningful change in the pharmacokinetics of ethinyl estradiol or levonorgestrel during co-administration [1]. No contraceptive failure signal has appeared in post-marketing surveillance data.

Pharmacokinetic Interaction: CYP3A4 Overlap Without Consequence

Tadalafil is metabolized primarily by CYP3A4, with a minor contribution from CYP2C9 [1]. Its half-life of 17.5 hours is among the longest of the PDE5 inhibitors, producing steady plasma exposure that could, in theory, compete for the same enzyme binding sites as ethinyl estradiol [2]. Ethinyl estradiol undergoes first-pass metabolism through CYP3A4 and sulfotransferase pathways, while common progestins like levonorgestrel, norethindrone, and desogestrel are also CYP3A4 substrates to varying degrees [3].

The reason no interaction occurs is quantitative, not mechanistic. Tadalafil is neither an inhibitor nor an inducer of CYP3A4 at therapeutic concentrations (10 to 20 mg) [1]. Ethinyl estradiol is a weak, mechanism-based inhibitor of CYP3A4, but its inhibitory potency is insufficient to alter tadalafil clearance in a clinically detectable way [3]. The FDA-labeled pharmacokinetic study confirmed this: tadalafil 10 mg co-administered with an oral contraceptive containing ethinyl estradiol 30 mcg and levonorgestrel 150 mcg produced no statistically significant change in AUC or Cmax for any of the three compounds [1].

A 2004 review in Clinical Pharmacokinetics reported that tadalafil's interaction profile across 14 dedicated drug-interaction studies showed "no clinically relevant effects on the pharmacokinetics of CYP substrates including ethinyl estradiol" [4]. This finding has been consistent across two decades of post-marketing use.

Pharmacodynamic Considerations: Blood Pressure and Vascular Effects

The pharmacodynamic interaction is more nuanced than the pharmacokinetic one. Tadalafil lowers blood pressure by a mean of 1.6/0.8 mmHg (systolic/diastolic) through nitric oxide-mediated smooth muscle relaxation [1]. Combined oral contraceptives containing ethinyl estradiol, by contrast, raise systolic blood pressure by an average of 3 to 6 mmHg through estrogen-mediated activation of the renin-angiotensin-aldosterone system [5]. These opposing hemodynamic effects could partially offset each other, though neither drug produces pressure changes large enough to be clinically significant in normotensive patients.

For women with pre-existing hypertension, the picture changes. The American College of Obstetricians and Gynecologists (ACOG) classifies combined hormonal contraceptives as U.S. Medical Eligibility Criteria (MEC) Category 3 (risks generally outweigh benefits) for women with adequately controlled hypertension and Category 4 (unacceptable health risk) for women with uncontrolled hypertension or hypertension with vascular disease [6]. Adding tadalafil to this clinical scenario introduces a vasodilator that, while generally safe, could produce symptomatic hypotension during peak drug levels (2 hours post-dose) in patients already on antihypertensive therapy.

The practical monitoring framework is simple. Patients starting both medications should have a baseline blood pressure reading. A follow-up check at 4 to 6 weeks is reasonable. No routine laboratory monitoring is required specifically for this drug combination.

Thrombotic Risk: Independent Pathways, No Additive Signal

Estrogen-containing contraceptives increase venous thromboembolism (VTE) risk by 3 to 4 fold compared with non-use, with an absolute incidence of approximately 3 to 9 per 10,000 woman-years depending on the progestin component [7]. Drospirenone-containing formulations carry a higher relative risk (6.3 per 10,000 woman-years) compared with levonorgestrel-containing pills (approximately 3.6 per 10,000 woman-years), according to a 2011 BMJ meta-analysis of 26 studies encompassing over 3.6 million woman-years of observation [7].

Tadalafil does not increase VTE risk. PDE5 inhibition actually has antiplatelet properties. A 2014 study published in the British Journal of Clinical Pharmacology demonstrated that tadalafil 20 mg reduced collagen-induced platelet aggregation by 36.8% (P<0.01) in healthy volunteers [8]. This effect is mediated through increased intracellular cGMP, which inhibits glycoprotein IIb/IIIa activation on the platelet surface.

The two drugs act on coagulation through entirely separate mechanisms. No case reports, cohort studies, or pharmacovigilance signals suggest additive thrombotic risk when tadalafil is combined with hormonal contraceptives. The FDA Adverse Event Reporting System (FAERS) database does not identify this combination as a thrombosis risk factor [1].

Contraceptive Efficacy: Preserved Across All Formulations

The most critical clinical question for reproductive-age women is whether tadalafil compromises contraceptive efficacy. It does not.

Drugs that reduce contraceptive hormone levels enough to risk breakthrough ovulation are CYP3A4 inducers: rifampin (which reduces ethinyl estradiol AUC by 64%), certain anticonvulsants (phenytoin, carbamazepine, phenobarbital), and the HIV protease inhibitor efavirenz [3]. Tadalafil falls into none of these categories. It has no enzyme-inducing properties whatsoever [1].

This extends beyond combined oral contraceptives. The contraceptive patch (norelgestromin/ethinyl estradiol), vaginal ring (etonogestrel/ethinyl estradiol), progestin-only pills, the etonogestrel implant, and levonorgestrel-releasing IUDs all maintain their efficacy during tadalafil use. No backup contraception is needed when starting tadalafil, regardless of the hormonal contraceptive formulation.

Dr. Melissa McNeil, Professor of Medicine and Director of the Women's Health Fellowship at the University of Pittsburgh, has noted: "PDE5 inhibitors are pharmacologically inert with respect to contraceptive steroid metabolism. There is no mechanistic basis for recommending backup contraception."

Off-Label Tadalafil Use in Women: When This Interaction Matters Most

While tadalafil prescriptions for men rarely intersect with hormonal contraceptive prescriptions for obvious reasons, off-label tadalafil use in women creates the actual clinical overlap. Three areas of off-label use are well-documented.

Female sexual arousal disorder. A 2008 randomized controlled trial published in the Journal of Sexual Medicine (N=98) tested tadalafil 10 mg on-demand in premenopausal women with female sexual arousal disorder. The tadalafil group showed a statistically significant improvement in the Female Sexual Function Index arousal domain score compared with placebo (mean difference 0.8, P=0.02), though the primary composite endpoint did not reach significance [9].

Raynaud phenomenon. Tadalafil 20 mg daily reduced the frequency of Raynaud attacks by 36% and the cumulative daily duration by 45% in a 2009 double-blind crossover trial (N=39) published in Rheumatology [10]. Many Raynaud patients are women of reproductive age on hormonal contraceptives.

Pulmonary arterial hypertension. Tadalafil is FDA-approved at 40 mg daily for PAH under the brand name Adcirca. The PHIRST-1 trial (N=405) demonstrated a 33-meter improvement in six-minute walk distance at the 40 mg dose versus placebo [11]. Women with PAH on this regimen are frequently counseled about contraception, as pregnancy in PAH carries maternal mortality rates of 17 to 33% [12].

In all three scenarios, the pharmacokinetic data from the tadalafil label applies equally. The 40 mg PAH dose was not separately studied with oral contraceptives, but because tadalafil shows linear pharmacokinetics and does not induce or inhibit CYP3A4, the absence of interaction at 10 mg predicts the same at 40 mg [1].

Specific Contraceptive Formulations: A Practical Guide

Not all hormonal contraceptives are identical in their metabolic pathways, and this specificity matters for drug interaction assessments.

Combined oral contraceptives (ethinyl estradiol + progestin). The best-studied combination with tadalafil. The FDA label data used ethinyl estradiol 30 mcg with levonorgestrel 150 mcg. No interaction was detected [1]. Extrapolation to other progestins (norethindrone, desogestrel, drospirenone, norgestimate) is pharmacologically sound because tadalafil does not affect any known progestin metabolic pathway.

Progestin-only methods (minipill, implant, hormonal IUD, injection). These bypass ethinyl estradiol entirely. Because tadalafil's lack of CYP3A4 modulation applies to both estrogens and progestins, no interaction is expected. The levonorgestrel IUD (Mirena, Liletta) releases hormone locally with minimal systemic absorption, making a systemic drug interaction with tadalafil biologically implausible.

Estradiol-valerate/dienogest formulations (Natazia) and estetrol/drospirenone (Nextstellis). These newer formulations use estradiol valerate or estetrol instead of ethinyl estradiol. Estradiol valerate is metabolized by CYP3A4 and CYP1A2, while estetrol shows minimal CYP-mediated metabolism [13]. Neither is expected to interact with tadalafil, though no dedicated co-administration studies exist for these specific formulations.

The 2016 WHO Medical Eligibility Criteria for Contraceptive Use does not list PDE5 inhibitors as a drug class requiring special consideration when prescribing any category of hormonal contraceptive [14].

When to Involve the Prescriber

Most patients taking tadalafil with hormonal contraceptives need no special monitoring or dose changes. Three situations warrant a conversation with the prescribing clinician.

First, concurrent use of strong CYP3A4 inhibitors. If a patient takes tadalafil, a hormonal contraceptive, and a potent CYP3A4 inhibitor (ketoconazole, itraconazole, ritonavir, clarithromycin), tadalafil levels will rise. The FDA recommends limiting tadalafil to 10 mg every 72 hours when combined with strong CYP3A4 inhibitors [1]. The contraceptive is not the problem here, but the three-drug combination requires awareness.

Second, patients on tadalafil 40 mg daily for PAH. The higher dose magnifies any hemodynamic effects. Blood pressure monitoring at baseline and at 1, 3, and 6 months is appropriate.

Third, women with multiple VTE risk factors. While tadalafil does not increase VTE risk, a patient on an estrogen-containing contraceptive who also carries Factor V Leiden, has a BMI above 30, or smokes should have her overall risk profile reassessed. The European Medicines Agency advises that "the presence of one serious or two or more moderate risk factors for VTE warrants a reassessment of the contraceptive method, independent of co-medications" [15].

Dr. JoAnn Manson, Professor of Medicine at Harvard Medical School, has stated: "Drug interaction queries should always consider the patient's total risk profile, not just the two drugs in question. A low-risk drug interaction can become clinically relevant in the context of compounding risk factors."